UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000007763
Receipt number R000009146
Scientific Title The comparison of the curative effect on benign prostatic hyperplasia between tamsulosin and naftopidil
Date of disclosure of the study information 2012/04/16
Last modified on 2012/04/16 01:28:13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The comparison of the curative effect on benign prostatic hyperplasia between tamsulosin and naftopidil

Acronym

The comparison between tamsulosin and naftopidil

Scientific Title

The comparison of the curative effect on benign prostatic hyperplasia between tamsulosin and naftopidil

Scientific Title:Acronym

The comparison between tamsulosin and naftopidil

Region

Japan


Condition

Condition

benign prostatic hyperplasia

Classification by specialty

Urology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the curative effect on benign prostatic hyperplasia between tamsulosin and naftopidil

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

International Prostate Symptom Score
Urinary flow rate
Residual urine

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

tamusulosin
12 weeks
0.2 mg
once a day

Interventions/Control_2

naftopidil
12 weeks
75 mg
once a day

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

The male patients who complain of urination disorder and suitable for alfa 1 blocker treatment
I-PSS total score higher than 8 and QOL score higher than 3
Maximum urinary flow rate lower than 10ml/s
Total prostate volume larger than 20ml

Key exclusion criteria

Active prostate cancer or history
The present illness which affect urinary condision
The history of the treatment with alfa 1 blocker and/or anticholinergic drug within 4 weeks
The history of the treatment with 5 alfa reductase inhibitor on benign prostatic hyperplasia
The history of the surgical treatment which affect urinary condition
The contraindication of alfa 1 blocker
The case which the chief urologist desides not adequate for the examination

Target sample size

60


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Noboru Sakamoto

Organization

Ibaraki Medical Center, Tokyo Medical University

Division name

Department of Urology

Zip code


Address

3-20-1 Chuo Amimachi Inasikigun, Ibaraki, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Noboru Sakamoto

Organization

Ibaraki Medical Center, Tokyo Medical University

Division name

Department of Urology

Zip code


Address


TEL

029-887-1161

Homepage URL


Email

uf.n.sakamoto@hotmail.com


Sponsor or person

Institute

Tokyo Medical University

Institute

Department

Personal name



Funding Source

Organization

nothing

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

東京医科大学茨城医療センター


Other administrative information

Date of disclosure of the study information

2012 Year 04 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2012 Year 04 Month 16 Day

Date of IRB


Anticipated trial start date

2012 Year 04 Month 01 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 04 Month 16 Day

Last modified on

2012 Year 04 Month 16 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009146


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name